Neurotrack is a leading company focused on developing digital biomarkers to detect cognitive decline and predict the risk of Alzheimer's disease and other neurodegenerative disorders. Founded in 2012 and headquartered in the United States, Neurotrack is pioneering non-invasive, clinically validated tests designed to detect early signs of cognitive impairment.

The company’s flagship product is its Neurotrack Cognitive Health Platform, which utilizes eye-tracking technology to measure cognitive function and predict the likelihood of future memory decline. This digital test assesses changes in a person's ability to focus and process information, providing valuable insights into early-stage Alzheimer's and other neurodegenerative conditions. By identifying cognitive decline at an earlier stage, Neurotrack aims to enable interventions that could slow or halt the progression of these diseases.